Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Activation of glucose-dependent insulinotropic polypeptide receptor (GIPR) has been shown to be protective against atherosclerosis. However, effects of GIP on the heart have remained unclear. To address this question, in vitro and in vivo experiments were conducted. METHODS AND RESULTS: In isolated mouse cardiomyocytes, GIPR mRNA was detected by reverse transcription-polymerase chain reaction, and GIP stimulation increased adenosine 3',5'-cyclic monophosphate production. In apolipoprotein E-knockout mice, infusion of angiotensin II (AngII; 2,000 ng·kg(-1)·min(-1)) significantly increased the heart weights, and co-administration of GIP (25 nmol·kg(-1)·day(-1)) reversed this increase (both P<0.01). In the left ventricular walls, GIP suppressed AngII-induced cardiomyocyte hypertrophy by 34%, apoptosis by 77%, and interstitial fibrosis by 79% (all P<0.01). Furthermore, GIP reduced AngII-induced expression of transforming growth factor-β1 (TGF-β1) and hypoxia inducible factor-1α. In wild-type mice, cardiac hypertrophy was induced by AngII to a lesser extent, and prevented by GIP. In contrast, GIP did not show any cardioprotective effect against AngII-induced cardiac hypertrophy in GIPR-knockout mice. In an in vitro experiment using mouse cardiomyocytes, GIP suppressed AngII-induced mRNA expression of B-type natriuretic peptide and TGF-β1. CONCLUSIONS: It was demonstrated that cardiomyocytes represent a direct target of GIP action in vitro, and that GIP ameliorated AngII-induced cardiac hypertrophy via suppression of cardiomyocyte enlargement, apoptosis, and fibrosis in vivo. (Circ J 2016; 80: 1988-1997).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodTransient Regenerative Potential of the Neonatal Mouse Heart
Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N., & Sadek, H. A. (2011) · Science · doi:10.1126/science.1200708 · Cited by 2,545 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodUsdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodSauer, B. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.6.2087 · Cited by 482
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodSelf-citationNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · cited 1×
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodSelf-citation
Cited by
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“GIP also reduces VSMC proliferation, arterial remodelling and nitric oxide synthesis 119 , cardiomyocyte hypertrophy, cardiac fibrosis and myocardial fatty acid metabolism and storage 12,120 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“Activation of GIPR signalling attenuates cardiac hypertrophy and fibrosis in mice with experimental hypertension [125], whereas loss of cardiomyocyte GIPR signalling is cardioprotective in mice with ischaemic cardiac injury secondary to coronary artery occlusion [124].”
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Metadata
- Authors
- Hiromura, M., Mori, Y., Kohashi, K., Terasaki, M., Shinmura, K., Negoro, T., Kawashima, H., Kogure, M., Wachi, T., Watanabe, R., Sato, K., Kushima, H., Tomoyasu, M., Nakano, Y., Yamada, Y., Watanabe, T., & Hirano, T.
- Venue
- Circulation Journal
- Publisher
- Japanese Circulation Society
- Published
- 2016
- Volume
- 80
- Issue
- 9
- Pages
- 1988-1997
- ISSN
- 1346-9843 (ISSN-L)
- 1347-4820
- OpenAlex
- W2471084456
- Cited by
- 52
- References
- 11
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models. https://app.cochat.ai/papers/10.1253/circj.cj-16-0152
- The paper
- Hiromura, M., Mori, Y., Kohashi, K., Terasaki, M., Shinmura, K., Negoro, T., Kawashima, H., Kogure, M., Wachi, T., Watanabe, R., Sato, K., Kushima, H., Tomoyasu, M., Nakano, Y., Yamada, Y., Watanabe, T., & Hirano, T. (2016). Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models. Circulation Journal. https://doi.org/10.1253/circj.cj-16-0152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.